A post-receptor defect of adenylyl cyclase in severely failing myocardium from children with congenital heart disease

Reithmann, Christopher; Reber, Daniela; Kozlik‐Feldmann, Rainer; Netz, Heinrich; Pilz, Günter; Welz, Armin; Werdan, Karl

doi:10.1016/s0014-2999(97)10131-5

Cited by 38 publications

(29 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The N-BNP levels of the 109 infants, children, and adolescents did not differ significantly from those measured in the 24 adults (303; 15 Reithmann et al, 16 and Läer et al 17 176 -626 fmol/mL; not significant). The 10th and the 90th percentiles of N-BNP in control children (11 days-17 years) was 150 and 430 fmol/mL, respectively (Fig 1).…”

Section: Plasma N-bnp Levels In Control Childrenmentioning

confidence: 67%

“…For patients aged Ͻ14 years, we used a modified scoring system described first by Ross 15 for infants with left-to-right shunt and modified by Reithmann et al 16 and Laer et al 17 Two physicians independently graded the following variables: diaphoresis, tachypnea, breathing with abdominal retractions, respiratory rate, heart rate, and hepatomegaly. These symptoms of CHF were graded on a scale of 0, 1, or 2 points according to the severity.…”

Section: Clinical Symptomsmentioning

confidence: 99%

See 1 more Smart Citation

Plasma Concentrations of N-Terminal Pro-Brain Natriuretic Peptide in Control Children From the Neonatal to Adolescent Period and in Children With Congestive Heart Failure

et al. 2002

View full text Add to dashboard Cite

ABSTRACT. Objective. To determine plasma levels of N-terminal pro-brain natriuretic peptide (N-BNP) in control children to establish a normal age-dependent range from the neonatal period to adulthood. In addition, plasma concentrations of N-BNP were measured in children with congestive heart failure (CHF) and correlated with ejection fraction and clinical symptoms of heart failure.Methods. For establishing a normal age-dependent range of plasma N-BNP, venous blood samples were taken in 133 control patients from the neonatal period to adulthood (10 days-32 years) and in 31 children with CHF. Plasma N-BNP levels were determined by an enzyme immunoassay. In children (1 month-14 years) with CHF, plasma N-BNP levels were correlated to ejection fraction measured by echocardiography and clinical symptoms of heart failure using the Ross Score.Results. N-BNP levels in control children, adolescents, and adults did not show a significant age-related difference. In control children, the normal range was established between 150 (10th percentile) and 430 fmol/mL (90th percentile). Mean plasma N-BNP in control children was 311 fmol/mL (range: 74 -654 fmol/mL). In 31 children with CHF, the plasma N-BNP levels were significantly higher (mean: 846; range: 219-2718) than in control children. N-BNP levels showed a negative correlation with the ejection fraction (r ‫؍‬ ؊0.53) and a positive correlation with the clinical heart failure score (r ‫؍‬ 0.74).Conclusions. Plasma N-BNP levels reflect the severity of symptoms of heart failure and the impairment of cardiac function in children with CHF. In the future, determination of plasma N-BNP levels may be used as a helpful adjunct to monitor the effect of various treatments for CHF in children. Pediatrics 2002;110(6). URL: http://www.pediatrics.org/cgi/content/full/110/6/e76; N-BNP, children, heart failure, natriuretic peptides.ABBREVIATIONS. BNP, brain natriuretic peptide; N-BNP, Nterminal pro-brain natriuretic peptide; CHF, congestive heart failure; DCM, dilated cardiomyopathy; HLHS, hypoplastic left heart syndrome, FALL, postoperative tetralogy of Fallot; MR, mitral regurgitation; VSD, ventricular septal defect; AVSD, atrioventricular septal defect.T he cardiac natriuretic hormones play an important role in the regulation of extracellular fluid volume and blood pressure. These peptide hormones induce natriuresis, diuresis, and vasodilation and act specifically to counter the effects of the renin-angiotensin-aldosterone system. The natriuretic peptide system allows the heart to participate in the regulation of vascular tone and extracellular volume status. The brain natriuretic peptide (BNP) is a recently discovered natriuretic hormone of cardiac origin. 1 BNP is secreted from the cardiac ventricular myocytes in response to an increase in ventricular wall tension and is related to left ventricular filling pressures. 2 BNP mediates in arterial and venous vasodilation. Human pro-BNP consists of 108 amino acids; processing releases the biologically active 32-amino acid peptide and an ami...

show abstract

Section: Plasma N-bnp Levels In Control Childrenmentioning

confidence: 67%

Section: Clinical Symptomsmentioning

confidence: 99%

Plasma Concentrations of N-Terminal Pro-Brain Natriuretic Peptide in Control Children From the Neonatal to Adolescent Period and in Children With Congestive Heart Failure

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Myocardial damage was monitored by the baseline venous blood level of creatine phosphokinase MB fraction and troponin-T, measured before skin incision, and every 4 hours after patient's admission to the ICU. These biochemical parameters were chosen as increase in their blood level is a highly sensitive and specific marker of cardiomyocytes damage [2,3]. These were measured in venous blood samples as the artery cannula was removed following patient's transfer from ICU to a specialized department, while the testing was continued till the fifth postoperative day.…”

Section: Methodsmentioning

confidence: 99%

First Results of ACH Cardioplegic Solution Clinical Application in Newborns and Infants under One Year of Age

Bockeriа¹,

Boldyrev²,

Kulaga³

et al. 2013

WJCD

View full text Add to dashboard Cite

Study objective involved comparison of two cardioplegic solutions: HTK-solution possessing high buffer capacity and a new ACH-solution with aminoacid buffer. Results revealed high cardioprotective efficiency during surgical repair of complex congenital heart disease both in the group that had received Custodiol and in the group that had received ACH-solution. Clinical and morphological parameters demonstrate high level of myocardial protection from intraoperative ischemia for single usage of ACH-solution during cardioplegic ischemia under 60 minutes in duration.

show abstract

“…(16)(17)(18)(19)(20)(21) Heart failure staging in infants and children is presented in Table II. (16) Classification of heart failure severity may include the New York Heart Association (NYHA) classification which is applicable only to adults and adolescents (17) (Table III); the Ross Classification which is applicable to children of all ages and cular dysfunction as the pulmonary pressures decrease postdelivery.…”

Section: Classification Of Heart Failurementioning

confidence: 99%

“…(18)(19)(20) Classification of heart failure in the paediatric population may also include The New York University Paediatric Heart Failure Index. (21) Like the NYHA classification, the Ross classification of severity of heart failure in children and infants has 4 classes as follows:…”

Section: Arrhythmiasmentioning

confidence: 99%

Aetiology, diagnosis and management of heart failure in infants and children

Pepeta

2017

SAHJ

View full text Add to dashboard Cite

A post-receptor defect of adenylyl cyclase in severely failing myocardium from children with congenital heart disease

Cited by 38 publications

References 16 publications

Plasma Concentrations of N-Terminal Pro-Brain Natriuretic Peptide in Control Children From the Neonatal to Adolescent Period and in Children With Congestive Heart Failure

Plasma Concentrations of N-Terminal Pro-Brain Natriuretic Peptide in Control Children From the Neonatal to Adolescent Period and in Children With Congestive Heart Failure

First Results of ACH Cardioplegic Solution Clinical Application in Newborns and Infants under One Year of Age

Aetiology, diagnosis and management of heart failure in infants and children

Contact Info

Product

Resources

About